2022
DOI: 10.1016/j.ajg.2022.01.005
|View full text |Cite
|
Sign up to set email alerts
|

Update on hepatorenal Syndrome: Definition, Pathogenesis, and management

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
8
0

Year Published

2022
2022
2023
2023

Publication Types

Select...
6

Relationship

1
5

Authors

Journals

citations
Cited by 9 publications
(8 citation statements)
references
References 87 publications
0
8
0
Order By: Relevance
“…When TBIL rises, the dilation of splanchnic vasculature and the intense increase in renal artery tone lead to renal cortex ischemia and hypoperfusion. This is one of the contributing factors that lead to the development of hepatorenal syndrome [ 33 ]. Sepsis also play an important role in the model.…”
Section: Discussionmentioning
confidence: 99%
“…When TBIL rises, the dilation of splanchnic vasculature and the intense increase in renal artery tone lead to renal cortex ischemia and hypoperfusion. This is one of the contributing factors that lead to the development of hepatorenal syndrome [ 33 ]. Sepsis also play an important role in the model.…”
Section: Discussionmentioning
confidence: 99%
“…Patients with advanced liver cirrhosis are at risk for developing the functional acute kidney injury (AKI) known as hepatorenal syndrome (HRS), which is linked to renal vasoconstriction after splanchnic vasodilatation (12) . Several factors, including ascites, serum creatinine >2.5 mg/dL, serum albumin 2 g/dL, serum total bilirubin >2 mg/dL, and spontaneous bacterial peritonitis, have been studied as predictors for HRS in patients with severe liver cirrhosis (13) .…”
Section: Discussionmentioning
confidence: 99%
“…A case-control study that included a total of 40 subjects; 30 patients with advanced liver cirrhosis, subdivided into; Group 1: 20 decompensated cirrhotic patients with hepatorenal syndrome (12…”
Section: Patients and Methods Study Designmentioning
confidence: 99%
“…Every year, FDA registers an increasing number of drugs belonging to this class. Almost half of the existing peptide drugs are compounds with one or several S–S bridges. , The most well-known among them are analogues of the natural hormones somatostatin, oxytocin, and vasopressin: octreotide, atosiban, terlipressin, etc. , Over the past 7 years, 6 radiopharmaceuticals based on octreotide have been approved . Atosiban (“Tractocile”), desmopressin (DDAVP) (“Minirin”), and terlipressin (“Remestyp”, “Terlivaz”, and “Glypressin”) are now firmly established in clinical practice. These drugs are structural analogues of oxytocin and Arg 8 /Lys 8 -vasopressin. Modifications of the native hormone structure, introduced in these peptides, are aimed at increasing their proteolytic stability and improving their pharmacokinetic characteristics. …”
Section: Introductionmentioning
confidence: 99%